These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 10607748)

  • 1. The CD44 variant isoforms CD44v6 and CD44v7 are expressed by distinct leukocyte subpopulations and exert non-overlapping functional activities.
    Seiter S; Schmidt DS; Zöller M
    Int Immunol; 2000 Jan; 12(1):37-49. PubMed ID: 10607748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional activity of murine CD44 variant isoforms in allergic and delayed type hypersensitivity.
    Wittig B; Seiter S; Föger N; Schwärzler C; Günthert U; Zöller M
    Immunol Lett; 1997 Jun; 57(1-3):217-23. PubMed ID: 9232455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitigation of delayed-type hypersensitivity reactions by a CD44 variant isoform v3-specific antibody: blockade of leukocyte egress.
    Seiter S; Engel P; Föhr N; Zöller M
    J Invest Dermatol; 1999 Jul; 113(1):11-21. PubMed ID: 10417612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44 variant isoforms on blood leukocytes in chronic inflammatory bowel disease and other systemic autoimmune diseases.
    Wittig B; Seiter S; Schmidt DS; Zuber M; Neurath M; Zöller M
    Lab Invest; 1999 Jun; 79(6):747-59. PubMed ID: 10378517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2-activated cytolytic lymphocytes.
    McKallip RJ; Fisher M; Do Y; Szakal AK; Gunthert U; Nagarkatti PS; Nagarkatti M
    J Biol Chem; 2003 Oct; 278(44):43818-30. PubMed ID: 12904302
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term treatment with anti-CD44v7 antibody, but not CD44v4, restores the gut mucosa in established chronic dextran sulphate sodium (DSS)-induced colitis in mice.
    Farkas S; Hornung M; Sattler C; Anthuber M; Gunthert U; Herfarth H; Schlitt HJ; Geissler EK; Wittig BM
    Clin Exp Immunol; 2005 Nov; 142(2):260-7. PubMed ID: 16232212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curative treatment of an experimentally induced colitis by a CD44 variant V7-specific antibody.
    Wittig B; Schwärzler C; Föhr N; Günthert U; Zöller M
    J Immunol; 1998 Aug; 161(3):1069-73. PubMed ID: 9686562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absence of specific alternatively spliced exon of CD44 in macrophages prevents colitis.
    Wittig BM; Sabat R; Holzlöhner P; Witte-Händel E; Heilmann K; Witte K; Triebus J; Tzankov A; Laman JD; Bokemeyer B; Terracciano L; Schwärzler C; Kohler H; Volkmer R; Loddenkemper C; Wolk K; Hoffmann U; Günthert U
    Mucosal Immunol; 2018 May; 11(3):846-860. PubMed ID: 29186109
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of experimental colitis correlates with increased apoptosis in mice deficient for CD44 variant exon 7 (CD44v7).
    Wittig BM; Johansson B; Zöller M; Schwärzler C; Günthert U
    J Exp Med; 2000 Jun; 191(12):2053-64. PubMed ID: 10859330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis.
    Heinzel FP; Sadick MD; Mutha SS; Locksley RM
    Proc Natl Acad Sci U S A; 1991 Aug; 88(16):7011-5. PubMed ID: 1908085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine lymph node antigen presenting cells are the main source of interleukin-6 in the initiation of delayed-type hypersensitivity.
    Ulrich P; Vohr HW
    Eur Cytokine Netw; 1996 Sep; 7(3):401-7. PubMed ID: 8954184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 promotes progenitor homing into the thymus and T cell maturation.
    Rajasagi M; Vitacolonna M; Benjak B; Marhaba R; Zöller M
    J Leukoc Biol; 2009 Feb; 85(2):251-61. PubMed ID: 18955544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD8+ T-cell subsets defined by expression of CD45 isoforms differ in their capacity to produce IL-2, IFN-gamma and TNF-beta.
    Adamthwaite D; Cooley MA
    Immunology; 1994 Feb; 81(2):253-60. PubMed ID: 7908892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Down-modulation of host reactivity by anti-CD44 in skin transplantation.
    Seiter S; Weber B; Tilgen W; Zöller M
    Transplantation; 1998 Sep; 66(6):778-91. PubMed ID: 9771842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune deviation of 2C transgenic intraepithelial lymphocytes in antigen-bearing hosts.
    Guehler SR; Bluestone JA; Barrett TA
    J Exp Med; 1996 Aug; 184(2):493-503. PubMed ID: 8760803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional activity of CD44 isoforms in haemopoiesis of the rat.
    Khaldoyanidi S; Schnabel D; Föhr N; Zöller M
    Br J Haematol; 1997 Jan; 96(1):31-45. PubMed ID: 9012685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 variant isoform expression in a variety of skin-associated autoimmune diseases.
    Seiter S; Schadendorf D; Tilgen W; Zöller M
    Clin Immunol Immunopathol; 1998 Oct; 89(1):79-93. PubMed ID: 9756727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD44v7 interferes with activation-induced cell death by up-regulation of anti-apoptotic gene expression.
    Marhaba R; Bourouba M; Zöller M
    J Leukoc Biol; 2003 Jul; 74(1):135-48. PubMed ID: 12832452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells.
    Xu H; DiIulio NA; Fairchild RL
    J Exp Med; 1996 Mar; 183(3):1001-12. PubMed ID: 8642241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-12 up-regulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production.
    Yoshimoto T; Takeda K; Tanaka T; Ohkusu K; Kashiwamura S; Okamura H; Akira S; Nakanishi K
    J Immunol; 1998 Oct; 161(7):3400-7. PubMed ID: 9759857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.